Novo Nordisk tapped Per Falk VP for clinical, medical and regulatory affairs for North America. Falk joined Novo Nordisk in 2002 and was most recently associate VP of clinical development and medical affairs for diabetes and metabolism products. In his new role, he will be responsible for clinical research and medical affairs in endocrinology and biopharmaceuticals as well as regulatory affairs and medical communications. He reports to president Jerzy Gruhn.
Acorda Therapeutics, a biotech focused on therapies for spinal cord injury, multiple sclerosis and related nervous system disorders, promoted Ruhi Khan to vice president, business development. Khan was previously executive director, business development. Prior to Acorda, Khan was senior director, business development at Lexicon Pharmaceuticals. She will report to CEO Ron Cohen.